ライフサイエンスコーパス: pointes

1 orphic ventricular tachycardia ('torsades de pointes').

2 ythmias (eg, long QT syndrome and torsade de pointes).

3 T interval and/or development of torsades de pointes).

4 methadone may be associated with torsade de pointes.

5 e thought to trigger episodes of torsades de pointes.

6 arket after being associated with torsade de pointes.

7 tion are not capable of inducing torsades de pointes.

8 ia displaying characteristics of torsades de pointes.

9 ial arrhythmias, but it can cause torsade de pointes.

10 the QT interval but rarely causes torsade de pointes.

11 the potentially fatal arrhythmia torsades de pointes.

12 the potential for development of torsade de pointes.

13 ricular arrhythmias, specifically torsade de pointes.

14 ymorphic ventricular tachycardia torsades de pointes.

15 nd an increased propensity toward torsade de pointes.

16 the link between hypokalemia and torsade de pointes.

17 T interval syndrome (diLQTS) and torsades de pointes.

18 rrhythmic agents known to promote torsade de pointes.

19 ificant predictor of drug-induced torsade de pointes.

20 abnormal heart rhythms, including torsade de pointes.

21 erventions to reduce the risk of torsades de pointes.

22 h the rare adverse drug reaction torsades de pointes.

23 ts including QT prolongation and torsades de pointes.

24 mine the risk of rare events like torsade de pointes.

25 tion of L-type channels, such as Torsades de Pointes.

26 rug-induced long QT syndrome and torsades de pointes.

27 afterdepolarizations (EADs), and torsade de pointes.

28 and the lethal cardiac arrhythmia torsade de pointes.

29 n are more vulnerable than men to torsade de pointes.

30 ation with the associated risk of torsade de pointes.

31 ndividuals to QT prolongation and torsade de pointes.

32 associated with case reports of torsades de pointes.

33 polarizations thought to trigger torsades de pointes.

34 ere was 1 episode of nonsustained torsade de pointes (1 of 70, 1.4%) after ibutilide.

35 arrests, with one resulting from Torsade de Pointes (6%).

36 Torsades de pointes, a form of ventricular tachycardia, has been rep

37 olong the QT interval and lead to torsade de pointes, a life-threatening ventricular arrhythmia, this

38 t in cases of QTc prolongation or torsade de pointes after dofetilide (a known proarrhythmic drug) an

39 acebo group (0.3% versus 0.1% for torsade de pointes and 0.9% versus 0.2% for severe neutropenia).

40 th complex arrhythmias including torsades de pointes and 2 degrees atrioventricular block.

41 Macrolides are known to cause torsade des pointes and other ventricular arrhythmias, and a recent

42 The incidences of torsade de pointes and severe neutropenia (absolute neutrophil coun

43 Prediction of torsade de pointes and sudden death can be improved by examining do

44 hanisms and establish the risk of torsade de pointes and sudden death with antipsychotic drugs.

45 dol have been documented to cause torsade de pointes and sudden death, the most marked risk is with t

46 f the role of noncardiac drugs in torsade de pointes and sudden death.

47 On the other hand, drug-induced torsades de pointes and symptomatic long QT syndrome have a female p

48 Another developed sustained torsade de pointes and was treated effectively with direct-current

49 morphic ventricular tachycardia (torsades de pointes) and sudden death.

50 result in ventricular arrhythmia (torsade de pointes) and sudden death.

51 orphous ventricular tachycardia (torsades de pointes), and sudden arrhythmic death.

52 e is burdened by QT prolongation, torsade de pointes, and sudden cardiac death.

53 Cases of QT prolongation, torsades de pointes, and sudden death have been reported with arseni

54 amilial and drug-induced cases of torsade de pointes, and the recognition of the role of noncardiac d

55 QT interval prolongation and torsade de pointes are associated with astemizole intake and have b

56 ective against dofetilide-induced torsade de pointes arrhythmias (TdP), while maintaining calcium hom

57 ated with an increased risk for Torsades des Pointes arrhythmias and sudden death.

58 Torsade de pointes arrhythmias could be induced during epicardial,

59 n the electrocardiogram and cause torsade de pointes arrhythmias not by direct block of the cardiac p

60 associated with life-threatening torsade de pointes arrhythmias that develop as a consequence of the

61 ave been associated with syncope, torsade de pointes arrhythmias, and sudden cardiac death.

62 nd fibrillations reminiscent of Torsades des Pointes arrhythmias, and they exhibit severely increased

63 predispose to the development of torsade de pointes arrhythmias.

64 tracellular calcium may underlie torsades de pointes associated with intravenous tacrolimus.

65 ently causes QT-prolongation and torsades de pointes cardiac arrhythmias.

66 ct which patients are at risk for torsade de pointes, careful assessment of the risk to benefit ratio

67 ing a persistent increase in TDR; Torsade de Pointes developed or could be induced only in the presen

68 a per se, determines the risk for torsade de pointes during atrioventricular block (AVB).

69 th diLQTS, defined as documented torsades de pointes during treatment with a QT-prolonging drug.

70 ing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolo

71 bservation of QT prolongation and torsade de pointes found with astemizole intake may principally be

72 They examine the risk for torsade de pointes from antipsychotic drugs and estimate the freque

73 ongation, potassium channels, and torsade de pointes from both the long QT syndrome and drugs.

74 es of prolonged QTc interval and torsades de pointes have been described in HIV-infected patients on

75 s developed in 7 patients (5.8%) (torsade de pointes in 2), significant bradycardia in 20 (16.7%) (ra

76 bservation of QT prolongation and torsade de pointes in a patient with undetectable serum concentrati

77 ftercontractions occurred before torsades de pointes in an in vivo dog model of drug-induced long-QT1

78 ificant predictor of drug-induced torsade de pointes in an independent sample of 216 cases compared w

79 amine susceptibility to acquired torsades de pointes in chronic atrioventricular block and for compar

80 duced BVR (P<0.01), and abolished torsade de pointes in hearts treated with either 20 nmol/L E-4031 o

81 surface cause QT prolongation and torsade de pointes in patients treated with As(2)O(3).

82 e-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals.

83 been recognized as a hallmark of torsade de pointes in the acquired LQTS, plays a major role in the

84 the mode of onset of spontaneous torsade de pointes in the congenital long QT syndrome.

85 o electrophysiologic mechanism of torsade de pointes in the long QT syndrome is described, using as a

86 higher incidences of drug-induced torsade de pointes in women than in men are incompletely defined, a

87 ictors of risk for progression to torsade de pointes, in addition to the degree of QT prolongation, w

88 rdiac medications known to cause torsades de pointes, including fluoroquinolones and intravenous halo

89 ly reports of QTc prolongation or torsade de pointes increased from a mean of 0.3 (95% CI, 0.1 to 0.5

90 on effect of many drugs producing torsade de pointes is block of the rapidly activating component of

91 T interval and the occurrence of torsades de pointes is similar to more expensive alternative medicat

92 The progression to torsade de pointes may be less related to degree of QT prolongation

93 darone, and drugs associated with torsade de pointes may have contributed to poor outcomes early in t

94 differences in propensity toward torsade de pointes may reflect the relatively greater presence in m

95 ata suggest that cisapride caused torsade de pointes not only by blocking IKr but also by rescuing ce

96 Torsade de pointes occurred after an abrupt acceleration of CL, whi

97 rsus WT (8/26; 31%; P<0.05), and Torsades de Pointes occurred more frequently (73% Cav3.1(-/-) versus

98 Two cases of torsade de pointes occurred, 1 on day 2 and the other on day 3 (0.8

99 fter ibutilide, only 1 episode of torsade de pointes occurred.

100 Torsade de pointes often occurs with underlying hypokalemia and bra

101 tricular block animals exhibited torsades de pointes on dofetilide, the arrhythmia was induced in onl

102 nce to suggest that this leads to torsade de pointes or sudden death.

103 the patients on sotalol developed Torsade de pointes or sustained ventricular arrhythmias.

104 patients with QT prolongation or torsade de pointes, or both, associated with protease inhibitors, u

105 tachycardia, ventricular flutter, torsade de pointes, or ventricular fibrillation.

106 drug-induced long QT syndrome and torsade de pointes pose unique challenges for clinicians, researche

107 ed in a patient with drug-induced torsade de pointes precipitated by the IKr blocker cisapride.

108 All drugs that cause torsade de pointes prolong the QTc interval and bind to the potassi

109 rugs, patients with low risk for torsades de pointes receiving selected class III agents, in whom dat

110 atient suffered recurrent runs of torsade de pointes, refractory to aggressive medical management and

111 Drug-induced QT prolongation and torsades de pointes remain significant and often unpredictable clini

112 ongation to be common (24%), with Torsade de Pointes representing 6% of in-hospital cardiac arrests.

113 ure was followed by an episode of torsade de pointes requiring immediate cardioversion.

114 on in hospitalized patients with torsades de pointes risk factors.

115 set of drugs with known clinical torsade de pointes risk was selected to develop and calibrate the i

116 The risk of torsades de pointes should be assessed in patients who are about to

117 nt with the propensity to induce torsades de pointes, substantially inhibits the current.

118 Torsades de pointes (TdP) +/-2 degrees atrioventricular block (AVB)

119 /L totally suppressed spontaneous torsade de pointes (TdP) and reduced the vulnerable window during w

120 long QT syndrome (LQTS) include torsades de pointes (TdP) and/or 2 degrees atrioventricular block, b

121 jects and may be associated with torsades de pointes (TdP) arrhythmia, we tested the hypothesis that

122 d and acquired long-QT associated torsade de pointes (TdP) arrhythmias, and sympathetic discharge is

123 cause of its propensity to induce torsade de pointes (TdP) arrhythmias.

124 Dose-dependent susceptibility to Torsade de Pointes (TdP) by class III drug dofetilide, 3, 10, and 3

125 chycardia with characteristics of torsade de pointes (TdP) developed in the presence of dl-sotalol.

126 re more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients exposed to

127 it hearts are more susceptible to torsade de pointes (TdP) in acquired long QT type 2 than males, in-

128 electrical instability leading to torsade de pointes (TdP) in LQTS are poorly understood.

129 tion (TDR) and the development of Torsade de Pointes (TdP) in models of LQT1, LQT2 and LQT3 forms of

130 re associated with initiation of torsades de pointes (TdP) in patients with acquired (a-) and congeni

131 study was to identify markers of torsades de pointes (TdP) in patients with drug-associated long QT s

132 may be related to the genesis of torsade de pointes (TdP) in patients with the long-QT (LQT) syndrom

133 sion of repolarization (TDR), and torsade de pointes (TdP) induced by beta-adrenergic agonists under

134 Drug-related torsade de pointes (TdP) is usually recognized within days of initi

135 The ventricular arrhythmia torsade de pointes (TdP) occurs after QT interval prolongation and

136 F, excessive QT prolongation and torsades de pointes (TdP) often occur shortly after sinus rhythm is

137 entry, giving rise to the typical torsade de pointes (TDP) pattern.

138 larization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2,

139 ciated with azimilide-associated torsades de pointes (TdP) ventricular tachycardia.

140 adjustment and the incidence of torsades de pointes (TdP) were identified.

141 ADs and the mechanisms underlying Torsade de Pointes (TdP) were investigated in a model of long QT sy

142 systolic activity and spontaneous torsade de pointes (TdP) were never observed, and stimulation-induc

143 n producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol

144 lmodulin inhibitor W-7 suppresses torsade de pointes (TdP) without shortening the QT interval, which

145 ization and increases the risk of Torsade de Pointes (TdP), a potentially lethal arrhythmia.

146 with documented prolonged QTc and Torsade de Pointes (TdP), and in an adult woman with QTc >500 ms, a

147 sk of lethal arrhythmias, called Torsades de pointes (TdP), compared to the opposite sex.

148 s can result in life-threatening torsades de pointes (TdP).

149 ulation despite its known risk of Torsade de pointes (TdP).

150 absent proarrhythmia markers for Torsade de Pointes (TdP).

151 g QRS morphology, better known as torsade de pointes (TdP).

152 ssociated with the development of torsade de pointes (TdP).

153 e-threatening arrhythmia known as Torsade de Pointes (TdP).

154 luding the risk of drug-induced 'torsades de pointes' (TdP) arrhythmia, is a major concern in the dev

155 Women have a higher incidence of torsades de pointes than men, but it is not known if the risk of dru

156 ng medications can predispose to torsades de pointes, there is a relative paucity of information that

157 correlate with a higher risk of torsades de pointes, there is no established threshold below which p

158 substrate for the development of torsade de pointes under long-QT conditions.

159 nown if the risk of drug-induced torsades de pointes varies during the menstrual cycle.

160 Torsade de pointes ventricular tachyarrhythmia in the long QT syndr

161 ction potential and propensity to torsade de pointes ventricular tachycardia.

162 There were no cases of torsades de pointes, ventricular fibrillation, or polymorphic or sus

163 Twelve documented cases of torsade de pointes VT were noted.

164 ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of the AFFIRM

165 The incidence of torsade de pointes was 0.6% at five years (95% confidence interval

166 Documentation of the onset of torsade de pointes was available for 15 patients.

167 Pause-dependent torsade de pointes was clearly documented in 14 of the 15 patients

168 When a drug associated with torsades de pointes was prescribed to a patient at moderate or high

169 as recorded in five patients, and torsade de pointes was recorded in seven other patients.

170 due to QTc prolongation, and no Torsades de Pointes was reported.

171 379 cases of QTc prolongation or torsade de pointes were associated with methadone.

172 lapsed APL developed asymptomatic torsade de pointes, which resolved spontaneously and did not recur

173 The characteristic association of torsade de pointes with T-wave alternans and short-long cardiac seq

174 lymorphic ventricular tachycardia torsade de pointes, with drugs or other environmental stressors suc